Chardan Healthcare Acquisition 2 Corp. (CHAQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chardan Healthcare Acquisition 2 Corp. (CHAQ) trades at $8.41 with AI Score 46/100 (Grade C). Chardan Healthcare Acquisition 2 Corp. is a shell company focused on acquiring assets and businesses through various methods like mergers and stock purchases. Sector: Financial services.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for CHAQ: CHAQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CHAQ against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CHAQ: the 1 perspectives are evenly split.
How is this calculated? →Chardan Healthcare Acquisition 2 Corp. (CHAQ) Financial Services Profile
Chardan Healthcare Acquisition 2 Corp., a special purpose acquisition company (SPAC) formed in 2018, aims to identify and merge with a private healthcare business, offering investors exposure to a potentially high-growth target without direct operational involvement, operating within the dynamic financial services sector.
What Is the Investment Thesis for CHAQ?
Chardan Healthcare Acquisition 2 Corp. presents an investment opportunity predicated on its ability to identify and merge with a high-growth healthcare company. The value driver is the potential upside from the acquired company's future performance. Key catalysts include the announcement and successful completion of a merger or acquisition, which is anticipated within the next 12-24 months. The company's management team's expertise in the healthcare sector and financial markets is crucial for identifying a suitable target. However, the investment is subject to risks, including the failure to find an appropriate target, unfavorable market conditions, and the potential for dilution if additional capital is required. Investors should carefully assess the terms of any proposed transaction and the prospects of the target company.
Based on FMP financials and quantitative analysis
CHAQ Key Highlights
- Founded in 2018, indicating a relatively young SPAC seeking a target company.
- Operates as a shell company, meaning its value is tied to its ability to complete a merger or acquisition.
- Focuses on the healthcare industry, providing potential exposure to a high-growth sector.
- Based in New York, offering access to a network of financial and healthcare professionals.
- Aims to provide a streamlined path for private healthcare companies to access public markets.
Who Are CHAQ's Competitors?
CHAQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DIST Distoken Acquisition Corporation | $28.00 | +0.00% | $89.60M | 44 |
| DPCS DP Cap Acquisition Corp I | $12.60 | -1.87% | $91.35M | 44 |
| GCTS GCT Semiconductor Holding, Inc. | $2.58 | -1.72% | $147.29M | — |
| GPAC Global Partner Acquisition Corp II | $9.74 | -21.45% | $89.56M | 46 |
| GWII Good Works II Acquisition Corp. | $10.11 | +0.00% | $89.72M | 44 |
| NSH NavSight Holdings, Inc. | $9.93 | +3.01% | 69 | |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.39M | 68 |
| LMAOU LMF Acquisition Opportunities, Inc. | $12.46 | +41.59% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CHAQ's Key Strengths?
- Experienced management team with healthcare and financial expertise.
- Access to capital through IPO.
- Flexibility to pursue a wide range of acquisition targets.
- Streamlined path to public markets for private companies.
What Are CHAQ's Weaknesses?
- Lack of operating history as a business.
- Dependence on finding a suitable acquisition target.
- Potential for dilution if additional capital is needed.
- Competition from other SPACs.
What Could Drive CHAQ Stock Higher?
- Announcement of a potential merger or acquisition target within the next 6-12 months.
- Completion of due diligence and negotiation of definitive agreements with the target company.
- Shareholder vote to approve the proposed merger or acquisition.
- Management team's efforts to identify and evaluate potential targets.
- Market conditions favorable to SPAC transactions.
What Are the Key Risks for CHAQ?
- Failure to find a suitable acquisition target within the allotted timeframe.
- Unfavorable market conditions impacting the valuation of potential targets.
- Regulatory scrutiny of the proposed merger or acquisition.
- Competition from other SPACs seeking acquisition targets.
- Risk of dilution if additional capital is required to complete the transaction.
What Are the Growth Opportunities for CHAQ?
- Identifying a High-Growth Healthcare Target: The primary growth opportunity lies in successfully identifying and merging with a high-growth healthcare company. The global healthcare market is projected to reach trillions of dollars by 2026, offering a vast pool of potential targets. A successful merger would provide investors with exposure to the target company's growth and innovation. The timeline for this opportunity is dependent on the company's ability to find and negotiate a deal, typically within 12-24 months of its IPO.
- Leveraging Management Expertise: Chardan Healthcare Acquisition 2 Corp. can leverage its management team's expertise in the healthcare sector and financial markets to identify and evaluate potential targets. Their experience can provide a competitive advantage in sourcing and negotiating favorable deals. This expertise can also help in assessing the long-term growth potential and strategic fit of potential targets. The ongoing value of this opportunity depends on the team's ability to adapt to evolving market conditions and identify emerging trends in the healthcare industry.
- Accessing Public Markets for Private Companies: Chardan Healthcare Acquisition 2 Corp. offers a streamlined path for private healthcare companies to access public markets, avoiding the complexities and time commitment associated with a traditional IPO. This can be a compelling option for companies seeking capital to fund growth or expansion. The demand for this alternative route to public markets is driven by the increasing number of innovative healthcare companies seeking funding and the evolving regulatory landscape. The timeline for this opportunity is dependent on the overall health of the IPO market and the attractiveness of SPACs as an alternative.
- Creating Value Through Operational Improvements: After completing a merger or acquisition, Chardan Healthcare Acquisition 2 Corp. can work with the target company to implement operational improvements and drive growth. This can involve streamlining operations, expanding into new markets, or developing new products and services. The success of this opportunity depends on the company's ability to identify and execute on these improvements, which can take several years to fully realize. The potential for value creation through operational improvements is significant, but it also requires careful planning and execution.
- Attracting Institutional Investors: By successfully completing a merger or acquisition, Chardan Healthcare Acquisition 2 Corp. can attract institutional investors who are seeking exposure to the healthcare sector. Institutional investors can provide long-term capital and support for the target company's growth initiatives. Attracting these investors requires demonstrating a clear growth strategy, strong financial performance, and a commitment to corporate governance. The timeline for attracting institutional investors is dependent on the company's ability to deliver on its promises and build a track record of success.
What Opportunities Does CHAQ Have?
- Growing demand for healthcare services and innovation.
- Increasing number of private healthcare companies seeking funding.
- Favorable market conditions for SPAC transactions.
- Potential to create significant value through successful acquisitions.
What Threats Does CHAQ Face?
- Regulatory scrutiny of SPAC transactions.
- Market volatility and economic downturn.
- Failure to find a suitable acquisition target.
- Competition from other SPACs and traditional IPOs.
What Are CHAQ's Competitive Advantages?
- Management team's expertise in the healthcare sector and financial markets.
- Access to a network of potential acquisition targets.
- Ability to provide a streamlined path for private companies to access public markets.
What Does CHAQ Do?
Chardan Healthcare Acquisition 2 Corp. was established in 2018 with the specific purpose of identifying and acquiring a promising business within the healthcare industry. As a special purpose acquisition company (SPAC), Chardan Healthcare Acquisition 2 Corp. does not have its own operational business. Instead, it raises capital through an initial public offering (IPO) with the intention of merging with or acquiring a private company, effectively taking that company public. The company's strategy involves leveraging the expertise of its management team to identify a target company with strong growth potential and attractive financial metrics. Based in New York, the company offers a streamlined path for private healthcare companies to access public markets, avoiding the complexities and time commitment associated with a traditional IPO. Chardan Healthcare Acquisition 2 Corp. focuses on creating value for its shareholders by facilitating a successful business combination that benefits both the acquired company and its investors. The ultimate success of Chardan Healthcare Acquisition 2 Corp. depends on its ability to identify, negotiate, and close a transaction with a suitable target company, which will then become the operating business.
What Products and Services Does CHAQ Offer?
- Identify and evaluate potential acquisition targets within the healthcare industry.
- Raise capital through an initial public offering (IPO) to fund acquisitions.
- Negotiate and execute merger or acquisition agreements with target companies.
- Provide a streamlined path for private healthcare companies to access public markets.
- Work with the acquired company to implement operational improvements and drive growth.
- Create value for shareholders through successful business combinations.
How Does CHAQ Make Money?
- Raise capital through an IPO, offering units consisting of shares and warrants.
- Seek to acquire a private healthcare company, taking it public through a merger.
- Generate returns for investors through the appreciation of the acquired company's stock.
- Management team may receive compensation and equity based on the successful completion of a merger.
What Industry Does CHAQ Operate In?
Chardan Healthcare Acquisition 2 Corp. operates within the shell company industry, specifically as a SPAC focused on the healthcare sector. The SPAC market has seen significant growth in recent years, offering an alternative route for companies to go public compared to traditional IPOs. This industry is characterized by intense competition among SPACs seeking attractive targets. The healthcare sector is a popular focus for SPACs due to its growth potential and innovation. However, regulatory scrutiny and market volatility can impact the success of SPAC transactions. The overall success of SPACs depends on their ability to identify and merge with high-quality companies that deliver long-term value to investors.
Who Are CHAQ's Key Customers?
- Private healthcare companies seeking to go public.
- Institutional investors seeking exposure to the healthcare sector.
- Retail investors interested in participating in SPAC investments.
How Chardan Healthcare Acquisition 2 Corp. Is Valued
Relative to its peer group, CHAQ's quantitative score of 46/100 is roughly in line with the peer average of 45/100.
Company Profile
Chardan Healthcare Acquisition 2 Corp. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in New York City, US. The company is led by CEO Gbolahan Amusa CFA. CHAQ has traded publicly since 2020.
CHAQ Financials
Bull Case vs Bear Case
Bull Case
- Experienced management team with healthcare and financial expertise.
- Access to capital through IPO.
- Flexibility to pursue a wide range of acquisition targets.
- Streamlined path to public markets for private companies.
Bear Case
- Lack of operating history as a business.
- Dependence on finding a suitable acquisition target.
- Potential for dilution if additional capital is needed.
- Competition from other SPACs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CHAQ Latest News
No recent news available for CHAQ.
CHAQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHAQ.
Price Targets
Wall Street price target analysis for CHAQ.
CHAQ MoonshotScore
What does this score mean?
The MoonshotScore rates CHAQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Shell CompaniesLeadership: Gbolahan Amusa CFA
CEO
Gbolahan Amusa is the Chief Executive Officer of Chardan Healthcare Acquisition 2 Corp. He is a CFA charterholder with extensive experience in the healthcare and financial sectors. His background includes roles in investment banking, equity research, and portfolio management. He has a proven track record of analyzing and investing in healthcare companies. Mr. Amusa's expertise spans various sub-sectors within healthcare, including pharmaceuticals, biotechnology, medical devices, and healthcare services. His experience makes him well-suited to lead Chardan Healthcare Acquisition 2 Corp. in its search for a suitable acquisition target.
Track Record: As CEO, Gbolahan Amusa is responsible for leading the company's efforts to identify and complete a merger or acquisition. His strategic decisions will be crucial in determining the success of the company. His prior experience in analyzing and investing in healthcare companies will be valuable in evaluating potential targets and negotiating favorable terms. The ultimate success of Chardan Healthcare Acquisition 2 Corp. will depend on his ability to execute a successful transaction.
Chardan Healthcare Acquisition 2 Corp. Financial Services Stock: Key Questions Answered
What does Chardan Healthcare Acquisition 2 Corp. do?
Chardan Healthcare Acquisition 2 Corp. is a special purpose acquisition company (SPAC) focused on the healthcare sector. It was formed to raise capital through an initial public offering (IPO) and then use those funds to acquire a private healthcare company, effectively taking it public. The company does not have its own operating business but instead seeks to identify and merge with a promising healthcare company with strong growth potential. The goal is to create value for shareholders by facilitating a successful business combination.
What do analysts say about CHAQ stock?
As a SPAC, Chardan Healthcare Acquisition 2 Corp.'s stock performance is primarily driven by the market's perception of its ability to find and complete a successful merger or acquisition. Analyst sentiment is generally focused on the quality of the management team, the attractiveness of the healthcare sector, and the overall market conditions for SPAC transactions. Key valuation metrics include the company's cash balance and the potential upside from the acquired company's future performance. Investors should carefully assess the terms of any proposed transaction and the prospects of the target company.
What are the main risks for CHAQ?
The main risks for Chardan Healthcare Acquisition 2 Corp. include the failure to find a suitable acquisition target within the allotted timeframe, unfavorable market conditions impacting the valuation of potential targets, and regulatory scrutiny of the proposed merger or acquisition. Competition from other SPACs seeking acquisition targets also poses a risk. Additionally, there is a risk of dilution if additional capital is required to complete the transaction. Investors should carefully consider these risks before investing in CHAQ.
What are the key factors to evaluate for CHAQ?
Chardan Healthcare Acquisition 2 Corp. (CHAQ) holds an AI score of 46/100 (low). Not financial advice.
How frequently does CHAQ data refresh on this page?
CHAQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CHAQ's recent stock price performance?
Chardan Healthcare Acquisition 2 Corp. (CHAQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Experienced management team with healthcare and financial expertise. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHAQ overvalued or undervalued right now?
Valuing Chardan Healthcare Acquisition 2 Corp. (CHAQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CHAQ?
Before investing in Chardan Healthcare Acquisition 2 Corp. (CHAQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for CHAQ, which could provide further insights.
- The success of CHAQ is dependent on factors outside of its direct control, such as market conditions and regulatory approvals.